Published in J Clin Oncol on August 14, 2006
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Clinical implications of the cancer genome. J Clin Oncol (2010) 3.11
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell (2009) 2.50
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst (2014) 2.29
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov (2012) 2.27
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell (2010) 2.06
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer (2008) 1.99
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 1.81
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer (2011) 1.73
Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov (2013) 1.71
Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma. Cancer (2009) 1.71
Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol (2012) 1.64
Gastrointestinal stromal tumor. J Gastrointest Oncol (2012) 1.57
Therapy for metastatic melanoma: the past, present, and future. BMC Med (2012) 1.57
A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol (2012) 1.57
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Primary anorectal melanoma: an update. J Cancer (2012) 1.55
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn (2011) 1.53
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res (2011) 1.47
Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol (2008) 1.44
Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer (2008) 1.43
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Whole-genome landscapes of major melanoma subtypes. Nature (2017) 1.40
BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One (2011) 1.40
A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer (2012) 1.38
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science (2014) 1.37
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest (2013) 1.34
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
Predictors of survival in mucosal melanoma of the head and neck. Ann Surg Oncol (2011) 1.29
C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch (2007) 1.26
The GIST paradigm: lessons for other kinase-driven cancers. J Pathol (2010) 1.26
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget (2013) 1.26
Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol (2011) 1.26
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int (2015) 1.25
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer (2010) 1.24
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol (2014) 1.22
Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol (2009) 1.21
Genetic risk factors for melanoma. Hum Genet (2009) 1.21
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res (2013) 1.20
Mucosal melanomas: a case-based review of the literature. Oncologist (2010) 1.20
A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One (2010) 1.17
Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer (2008) 1.17
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
A melanoma molecular disease model. PLoS One (2011) 1.15
Melanocytes in development and cancer. J Cell Physiol (2010) 1.15
Low incidence of KIT gene mutations and no PDGFRA gene mutations in primary cutaneous melanoma: an immunohistochemical and molecular genetic study of Japanese cases. Int J Clin Oncol (2010) 1.14
Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer (2008) 1.14
Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene (2009) 1.14
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med (2008) 1.13
Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13
Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol (2010) 1.13
Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis (2010) 1.11
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res (2013) 1.10
Ipilimumab for patients with advanced mucosal melanoma. Oncologist (2013) 1.09
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer (2012) 1.07
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov (2011) 1.07
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol (2014) 1.07
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res (2010) 1.07
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc (2014) 1.06
MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis (2012) 1.06
The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys (2011) 1.04
Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract (2014) 1.04
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res (2009) 1.03
New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res (2012) 1.01
Lack of SF3B1 R625 mutations in cutaneous melanoma. Diagn Pathol (2013) 1.00
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs (2011) 1.00
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma. Expert Rev Dermatol (2007) 0.98
Amelanotic malignant melanoma of the esophagus: report of two cases with immunohistochemical and molecular genetic study of KIT and PDGFRA. World J Gastroenterol (2009) 0.98
Genetics and genomics of melanoma. Expert Rev Dermatol (2009) 0.98
Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer (2010) 0.97
GAB2 amplifications refine molecular classification of melanoma. Clin Cancer Res (2009) 0.97
KIT as a therapeutic target in melanoma. J Invest Dermatol (2010) 0.97
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat Commun (2013) 0.97
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Fine-scale structural variation of the human genome. Nat Genet (2005) 24.31
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Segmental duplications and copy-number variation in the human genome. Am J Hum Genet (2005) 13.33
Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. Nat Genet (2006) 10.36
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Linkage disequilibrium and heritability of copy-number polymorphisms within duplicated regions of the human genome. Am J Hum Genet (2006) 7.70
A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet (2004) 7.68
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol (2005) 4.79
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
Genomic microarrays in human genetic disease and cancer. Hum Mol Genet (2003) 4.15
Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH. Genome Res (2003) 4.10
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst (2003) 3.65
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Fully automatic quantification of microarray image data. Genome Res (2002) 3.47
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene (2005) 2.99
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res (2003) 2.62
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet (2005) 2.51
Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell (2012) 2.50
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Large-scale variation among human and great ape genomes determined by array comparative genomic hybridization. Genome Res (2003) 2.41
Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res (2003) 2.34
Regional copy number-independent deregulation of transcription in cancer. Nat Genet (2006) 2.33
Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res (2009) 2.27
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol (2003) 2.18
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood (2006) 2.10
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst (2005) 2.10
Primary mucosal malignant melanoma of the head and neck. Head Neck (2002) 2.07
Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol (2003) 2.05
Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol (2006) 2.04
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98
Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev (2007) 1.98
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res (2002) 1.96
Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol (2004) 1.87
Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol (2009) 1.87
Ambiguous melanocytic tumors with loss of 3p21. Am J Surg Pathol (2014) 1.83
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 1.81
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res (2006) 1.80
A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol (2006) 1.80
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78
Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev (2007) 1.76
MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72
Mapping segmental and sequence variations among laboratory mice using BAC array CGH. Genome Res (2005) 1.71
Shaping of tumor and drug-resistant genomes by instability and selection. Oncogene (2003) 1.70
MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood (2003) 1.69
A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Hum Mol Genet (2002) 1.69
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res (2003) 1.67
Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol (2002) 1.62
High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol (2003) 1.57
A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol (2012) 1.57
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene (2003) 1.52
Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood (2005) 1.51
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev (2006) 1.51
Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat Genet (2002) 1.48
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res (2011) 1.47
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer Immun (2007) 1.46
Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol (2004) 1.46
Metastatic melanoma in association with a giant congenital melanocytic nevus in an adult: controversial CGH findings. Am J Dermatopathol (2015) 1.45
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol (2012) 1.45
Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control (2007) 1.44
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
The presence of polyomavirus in non-melanoma skin cancer in organ transplant recipients is rare. J Invest Dermatol (2008) 1.43
Genomic profiling of gastric cancer predicts lymph node status and survival. Oncogene (2003) 1.40
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood (2002) 1.40
Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med (2004) 1.38
Solar elastotic material in dermal lymphatics and lymph nodes. Am J Surg Pathol (2010) 1.38
Trichodysplasia spinulosa is characterized by active polyomavirus infection. J Clin Virol (2011) 1.36
Long-term outcome of perianal Paget's disease. Dis Colon Rectum (2003) 1.35
Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res (2007) 1.34
Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. Carcinogenesis (2005) 1.32
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A (2002) 1.30
High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer (2003) 1.25
Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res (2012) 1.23
Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J Pathol (2003) 1.21
Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am J Pathol (2002) 1.21
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res (2013) 1.20
Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol (2008) 1.19
PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol (2006) 1.19